{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:13:05Z","timestamp":1767985985027,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2790,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1093\/annonc\/mdr346","type":"journal-article","created":{"date-parts":[[2011,8,3]],"date-time":"2011-08-03T00:17:49Z","timestamp":1312330669000},"page":"990-996","source":"Crossref","is-referenced-by-count":39,"title":["Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients"],"prefix":"10.1016","volume":"23","author":[{"given":"U.","family":"Brunnberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Noppeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.A.","family":"D\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Sauerland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Mesters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"B\u00fcchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ehninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Serve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr346_bb0010","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr346_bb0020","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.1985.3.12.1583","article-title":"Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group","volume":"3","author":"B\u00fcchner","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr346_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"B\u00fcchner","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr346_bb0030","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s00277-004-0889-0","article-title":"Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia","volume":"83","author":"Hofmann","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdr346_bb0035","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1200\/JCO.2003.02.133","volume":"21","author":"B\u00fcchner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr346_bb0040","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr346_bb0045","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr346_bb0050","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/1097-0142(19910915)68:6<1198::AID-CNCR2820680603>3.0.CO;2-E","article-title":"Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia","volume":"68","author":"Arlin","year":"1991","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr346_bb0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.leukres.2007.06.015","article-title":"Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis","volume":"32","author":"Kessler","year":"2008","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdr346_bb0060","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bc0100206","article-title":"An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug Chem"},{"key":"10.1093\/annonc\/mdr346_bb0065","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr346_bb0070","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr346_bb0075","first-page":"657","article-title":"Gemtuzumab ozogamicin (Mylotarg) for the treatment of acute myeloid leukemia\u2014ongoing trials","volume":"30","author":"Gleissner","year":"2007","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/mdr346_bb0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.leukres.2004.04.011","article-title":"Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older","volume":"29","author":"Nabhan","year":"2005","journal-title":"Leukemia Res"},{"key":"10.1093\/annonc\/mdr346_bb0085","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr346_bb0090","first-page":"4173","article-title":"Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype","volume":"58","author":"Bloomfield","year":"1998","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr346_bb0095","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0100","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0105","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2002-02-0532","article-title":"Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial","volume":"101","author":"Kern","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0115","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V114.22.653.653","article-title":"Defibrotide (DF) for the prevention of hepatic veno-occlusive disease (VOD) in pediatric stem cell transplantation: results of a prospective phase II\/III randomized, multicenter trial","volume":"114","author":"Corbacioglu","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V114.22.654.654","article-title":"Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF) following stem cell transplantation (SCT): results of a phase 3 study utilizing a historical control","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML 15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr346_bb0130","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood.V112.11.762.762","article-title":"Phase II-III study of gemtuzumab ozogamicin monotherapy versus best supportive care in older patients with newly diagnosed AML unfit for intensive chemotherapy: first results of the EORTC-GIMEMA AML-19 trial","volume":"112","author":"Amadori","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0135","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V114.22.790.790","volume":"114","author":"Petersdorf","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0140","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2009-10-246470","article-title":"Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a phase III study","volume":"115","author":"L\u00f6wenberg","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V116.21.18.18","article-title":"The addition of gemtuzumab ozogamicin to low dose ara-C improves remission rates but not survival: results of the UK LRF AML14 and NCRI AML16 \u201cpick a winner\u201d comparison","volume":"116","author":"Burnett","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr346_bb0150","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.leukres.2004.01.009","article-title":"First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients","volume":"28","author":"Piccaluga","year":"2004","journal-title":"Leukemia Res"},{"key":"10.1093\/annonc\/mdr346_bb0155","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1200\/JCO.2005.04.5013","article-title":"Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia","volume":"24","author":"B\u00fcchner","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419346460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/4\/990\/546827\/mdr346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T13:14:33Z","timestamp":1627478073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419346460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0923753419346460"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr346","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}